Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Sees Large Drop in Short Interest

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) saw a large drop in short interest in September. As of September 15th, there was short interest totalling 97,700 shares, a drop of 9.4% from the August 31st total of 107,800 shares. Based on an average daily volume of 2,070,000 shares, the short-interest ratio is currently 0.0 days. Currently, 0.6% of the shares of the company are sold short.

Bluejay Diagnostics Trading Down 9.4 %

NASDAQ:BJDX opened at $0.13 on Tuesday. The company’s 50 day moving average is $0.28 and its two-hundred day moving average is $2.59. The company has a market cap of $42,672.00, a PE ratio of 0.00 and a beta of 0.73. Bluejay Diagnostics has a twelve month low of $0.12 and a twelve month high of $38.96.

Bluejay Diagnostics (NASDAQ:BJDX) last released its earnings results on Wednesday, August 14th. The company reported ($5.12) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC bought a new position in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 24,230 shares of the company’s stock, valued at approximately $30,000. Armistice Capital LLC owned about 1.95% of Bluejay Diagnostics as of its most recent SEC filing. Institutional investors own 18.47% of the company’s stock.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.